PAVmed And Momo On The List Of Winners And Losers Of Thursday’s US Session

(VIANEWS) – Another day of trading has ended and here’s today‚Äôs list of stocks that have had significant trading activity in the US session.

The three biggest winners today are PAVmed, PowerFleet, and Ontrak.

Rank Financial Asset Price Change Updated (EST)
1 PAVmed (PAVMW) 0.03 105.67% 2024-03-14 03:08:05
2 PowerFleet (PWFL) 3.92 10.11% 2024-03-14 11:13:05
3 Ontrak (OTRK) 0.18 8.69% 2024-03-14 01:11:05
4 Oric Pharmaceuticals (ORIC) 15.23 6.35% 2024-03-13 23:48:05
5 Ocugen (OCGN) 1.04 5.69% 2024-03-13 21:10:06
6 TDH Holdings (PETZ) 1.23 5.13% 2024-03-14 03:48:05
7 Kosmos Energy (KOS) 5.81 4.68% 2024-03-14 15:56:18
8 FibroGen (FGEN) 2.09 4.5% 2024-03-14 15:12:11
9 Shinhan Financial Group (SHG) 37.74 4.43% 2024-03-14 15:58:33
10 OneSpaWorld Holdings Limited (OSW) 13.24 4.17% 2024-03-14 01:08:05

The three biggest losers today are Momo, Puyi, and Futu Holdings.

Rank Financial Asset Price Change Updated (EST)
1 Momo (MOMO) 5.96 -22.29% 2024-03-14 15:13:38
2 Puyi (PUYI) 6.74 -21.17% 2024-03-14 11:10:05
3 Futu Holdings (FUTU) 56.40 -13.76% 2024-03-14 15:16:24
4 PAVmed (PAVM) 2.16 -13.6% 2024-03-14 03:07:06
5 Phunware (PHUN) 9.20 -11.54% 2024-03-14 05:12:06
6 Redfin (RDFN) 6.32 -11.24% 2024-03-14 15:17:07
7 Relay Therapeutics (RLAY) 8.17 -10.61% 2024-03-14 16:23:06
8 MicroVision (MVIS) 2.08 -10.17% 2024-03-14 15:13:47
9 Viking Therapeutics (VKTX) 65.05 -9.6% 2024-03-14 15:17:44
10 Oportun Financial Corporation (OPRT) 3.65 -9.2% 2024-03-13 23:15:05

Winners today

1. PAVmed (PAVMW) – 105.67%

NASDAQ ended the session with PAVmed rising 105.67% to $0.03 on Thursday while NASDAQ dropped 0.3% to $16,128.53.

Moving Average

PAVmed’s value is way below its 50-day moving average of $0.21 and way below its 200-day moving average of $1.66.

More news about PAVmed.

2. PowerFleet (PWFL) – 10.11%

PowerFleet, Inc. provides wireless Internet-of-Things asset management solutions in the United States, Israel, and internationally. The company offers real-time intelligence for organizations to capture IoT data from various types of assets with devices and sensors to increase efficiencies, and improve safety and security, as well as increase their profitability in easy-to-understand reports, dashboards, and real-time alerts; and application programming interfaces for additional integrations and development to boost other enterprise management systems and third-party applications. It also provides hosting, maintenance, and support and consulting services; and Software as a Service, including system monitoring, help desk technical support, escalation procedure development, routine diagnostic data analysis, and software updates services. The company offers its products under the PowerFleet, Pointer, and Cellocator brands. It sells its products to commercial and government sectors in manufacturing, automotive manufacturing, wholesale and retail, food and grocery distribution, pharmaceutical and medical distribution, construction, mining, utilities, heavy industry, aerospace and defense, homeland security, and vehicle rental, logistics, shipping, and freight transportation markets, as well as through indirect sales channels, such as original equipment manufacturers, vehicle importers, distributors, and industrial equipment dealers. The company was formerly known as I.D. Systems, Inc. PowerFleet, Inc. was incorporated in 1993 and is headquartered in Woodcliff Lake, New Jersey.

NASDAQ ended the session with PowerFleet rising 10.11% to $3.92 on Thursday while NASDAQ dropped 0.3% to $16,128.53.

Earnings Per Share

As for profitability, PowerFleet has a trailing twelve months EPS of $-0.25.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -3.68%.

More news about PowerFleet.

3. Ontrak (OTRK) – 8.69%

Ontrak, Inc. operates as an artificial intelligence powered, telehealth-enabled, and virtualized healthcare company that provides in-person services to third-party payors in the United States. Its technology-enabled platform predicts people whose chronic disease will improve with behavior change, recommends effective care pathways that people are willing to follow, and engages and guides them to and through the care they need. The company's technology enabled OnTrak program provides healthcare solutions to members with behavioral conditions that cause or exacerbate chronic medical conditions, such as diabetes, hypertension, coronary artery disease, chronic obstructive pulmonary disease, and congestive heart failure. The OnTrak integrates evidence-based psychosocial and medical interventions delivered in-person or via telehealth along with care coaching and in-market community care coordinators, who address the social and environmental determinants of health. The company was formerly known as Catasys, Inc. and changed its name to Ontrak, Inc. in July 2020. The company was incorporated in 2003 and is headquartered in Henderson, Nevada.

NASDAQ ended the session with Ontrak rising 8.69% to $0.18 on Thursday while NASDAQ slid 0.3% to $16,128.53.

Earnings Per Share

As for profitability, Ontrak has a trailing twelve months EPS of $-8.03.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -714.32%.

More news about Ontrak.

4. Oric Pharmaceuticals (ORIC) – 6.35%

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. ORIC Pharmaceuticals, Inc. has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

NASDAQ ended the session with Oric Pharmaceuticals rising 6.35% to $15.23 on Thursday while NASDAQ dropped 0.3% to $16,128.53.

Earnings Per Share

As for profitability, Oric Pharmaceuticals has a trailing twelve months EPS of $-1.96.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -45.11%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 13.2% and 6%, respectively.

Yearly Top and Bottom Value

Oric Pharmaceuticals’s stock is valued at $15.23 at 17:32 EST, below its 52-week high of $16.65 and way higher than its 52-week low of $4.30.

Moving Average

Oric Pharmaceuticals’s worth is way higher than its 50-day moving average of $11.37 and way higher than its 200-day moving average of $8.45.

More news about Oric Pharmaceuticals.

5. Ocugen (OCGN) – 5.69%

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

NASDAQ ended the session with Ocugen jumping 5.69% to $1.04 on Thursday, after two successive sessions in a row of gains. NASDAQ slid 0.3% to $16,128.53, following the last session’s downward trend on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, Ocugen has a trailing twelve months EPS of $-0.32.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -98.28%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Ocugen’s EBITDA is -2.53.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 40% and 14.3%, respectively.

Yearly Top and Bottom Value

Ocugen’s stock is valued at $1.04 at 17:32 EST, way under its 52-week high of $1.28 and way higher than its 52-week low of $0.35.

More news about Ocugen.

6. TDH Holdings (PETZ) – 5.13%

TDH Holdings, Inc. engages in the restaurant operation business in the United States. Its restaurants provide dining area, bar, catering services, and space for banquets. The Company also runs restaurant business in the United States. TDH Holdings, Inc. was founded in 2002 and is based in Qingdao, the People's Republic of China.

NASDAQ ended the session with TDH Holdings rising 5.13% to $1.23 on Thursday while NASDAQ slid 0.3% to $16,128.53.

Earnings Per Share

As for profitability, TDH Holdings has a trailing twelve months EPS of $0.2.

PE Ratio

TDH Holdings has a trailing twelve months price to earnings ratio of 6.15. Meaning, the purchaser of the share is investing $6.15 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.47%.

Moving Average

TDH Holdings’s value is higher than its 50-day moving average of $1.14 and above its 200-day moving average of $1.20.

More news about TDH Holdings.

7. Kosmos Energy (KOS) – 4.68%

Kosmos Energy Ltd., together with its subsidiaries, engages in the exploration, development, and production of oil and gas along the Atlantic Margins in the United States. The company's primary assets include production projects located in offshore Ghana, Equatorial Guinea, and the U.S. Gulf of Mexico, as well as gas projects located in offshore Mauritania and Senegal. It undertakes a proven basin exploration program in Equatorial Guinea and the U.S. Gulf of Mexico. Kosmos Energy Ltd. was founded in 2003 and is headquartered in Dallas, Texas.

NYSE ended the session with Kosmos Energy jumping 4.68% to $5.81 on Thursday, following the last session’s upward trend. NYSE fell 0.73% to $17,886.27, after two sequential sessions in a row of gains, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, Kosmos Energy has a trailing twelve months EPS of $0.44.

PE Ratio

Kosmos Energy has a trailing twelve months price to earnings ratio of 13.2. Meaning, the purchaser of the share is investing $13.2 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.19%.

Sales Growth

Kosmos Energy’s sales growth is negative 15.3% for the current quarter and negative 3.9% for the next.

Revenue Growth

Year-on-year quarterly revenue growth grew by 15.4%, now sitting on 1.71B for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Kosmos Energy’s stock is considered to be overbought (>=80).

More news about Kosmos Energy.

8. FibroGen (FGEN) – 4.5%

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

NASDAQ ended the session with FibroGen rising 4.5% to $2.09 on Thursday, after two successive sessions in a row of gains. NASDAQ slid 0.3% to $16,128.53, following the last session’s downward trend on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, FibroGen has a trailing twelve months EPS of $-2.92.

Earnings Before Interest, Taxes, Depreciation, and Amortization

FibroGen’s EBITDA is 0.64.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 49.4% and 55.6%, respectively.

Yearly Top and Bottom Value

FibroGen’s stock is valued at $2.09 at 17:32 EST, way below its 52-week high of $20.90 and way above its 52-week low of $0.33.

Moving Average

FibroGen’s value is way above its 50-day moving average of $1.52 and way under its 200-day moving average of $3.01.

More news about FibroGen.

9. Shinhan Financial Group (SHG) – 4.43%

Shinhan Financial Group Co., Ltd. provides financial products and services in South Korea and internationally. The company operates through six segments: Banking, Credit Card, Securities, Life Insurance, Credit, and Others. It offers retail banking services, including demand, savings, and fixed deposit-taking; checking accounts; mortgage and home equity, and retail lending; electronic banking and automatic teller machines (ATM); and bill paying, payroll and check-cashing, currency exchange, and wire fund transfer services. The company also provides corporate banking services, such as investment banking, real estate financing, overseas real estate and development project financing, infrastructure and structured financing, equity/venture investments, mergers and acquisitions consulting; securitization and derivatives services comprising securities and derivative products, and foreign exchange trading; and working capital loans and facilities loans. In addition, it is involved in treasury and investment activities in international capital markets consisting of foreign currency-denominated securities trading, foreign exchange trading and services, trade-related financial services, international factoring services, and foreign banking operations. Further, the company offers real estate trust, investment advisory, venture capital, non-life insurance, trust account management, securities brokerage, and asset management services, as well as leasing and equipment financing, savings banking, loan collection and credit reporting, collective investment administration, private equity investment, and financial system development services. Shinhan Financial Group Co., Ltd. was founded in 1982 and is headquartered in Seoul, South Korea.

NYSE ended the session with Shinhan Financial Group rising 4.43% to $37.74 on Thursday, following the last session’s upward trend. NYSE fell 0.73% to $17,886.27, after two successive sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, Shinhan Financial Group has a trailing twelve months EPS of $5.81.

PE Ratio

Shinhan Financial Group has a trailing twelve months price to earnings ratio of 6.5. Meaning, the purchaser of the share is investing $6.5 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.36%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 42%, now sitting on 14.18T for the twelve trailing months.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on Feb 22, 2024, the estimated forward annual dividend rate is 1.59 and the estimated forward annual dividend yield is 4.86%.

Volume

Today’s last reported volume for Shinhan Financial Group is 176463 which is 34.26% above its average volume of 131433.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter is 67.5% and a drop 9.5% for the next.

More news about Shinhan Financial Group.

10. OneSpaWorld Holdings Limited (OSW) – 4.17%

OneSpaWorld Holdings Limited operates health and wellness centers onboard cruise ships and at destination resorts worldwide. Its health and wellness centers offer services, such as traditional body, salon, and skin care services and products; self-service fitness facilities, specialized fitness classes, and personal fitness training; pain management, detoxifying programs, and body composition analyses; weight management programs and products; and medi-spa services. The company also provides its guests access to beauty and wellness brands, including ELEMIS, Kérastase, Restylane, BOTOX Cosmetic, Perlane, Thermage, CoolSculpting, truSculpt 3D, truSculpt iD, and Dysport with various brands offered in the cruise market. The company is based in Nassau, Bahamas.

NASDAQ ended the session with OneSpaWorld Holdings Limited jumping 4.17% to $13.24 on Thursday, after two sequential sessions in a row of gains. NASDAQ fell 0.3% to $16,128.53, following the last session’s downward trend on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, OneSpaWorld Holdings Limited has a trailing twelve months EPS of $-0.03.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -0.74%.

Volume

Today’s last reported volume for OneSpaWorld Holdings Limited is 870615 which is 35.13% above its average volume of 644270.

Revenue Growth

Year-on-year quarterly revenue growth grew by 15.3%, now sitting on 794.04M for the twelve trailing months.

Sales Growth

OneSpaWorld Holdings Limited’s sales growth is 19.9% for the present quarter and 7.9% for the next.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 30.8% and 20%, respectively.

More news about OneSpaWorld Holdings Limited.

Losers Today

1. Momo (MOMO) – -22.29%

Hello Group Inc. provides mobile-based social and entertainment services in the People's Republic of China. The company offers Momo, a mobile application that connects people and facilitates social interactions based on location, interests, and various online recreational activities including, live talent shows, short videos, social games, as well as other video- and audio-based interactive experiences, such as online parties, mobile karaoke and user participated reality shows; Tantan, a social and dating application; and other applications under the Hertz, Soulchill, Duidui, and Tietie names. The company also provides livestream services for various content and activities comprising talent shows, such as singing, dancing, and talk shows, as well as casual chatting, and other forms of interactions between broadcasters and viewers to its platform's users; value-added services; advertising and marketing services; and mobile games. The company was formerly known as Momo Inc. and changed its name to Hello Group Inc. in August 2021. Hello Group Inc. was incorporated in 2011 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with Momo dropping 22.29% to $5.96 on Thursday while NASDAQ fell 0.3% to $16,128.53.

Earnings Per Share

As for profitability, Momo has a trailing twelve months EPS of $1.32.

PE Ratio

Momo has a trailing twelve months price to earnings ratio of 4.52. Meaning, the purchaser of the share is investing $4.52 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17%.

Volatility

Momo’s last week, last month’s, and last quarter’s current intraday variation average was 2.15%, 1.09%, and 1.82%.

Momo’s highest amplitude of average volatility was 2.30% (last week), 1.92% (last month), and 1.82% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Momo’s stock is considered to be oversold (<=20).

Revenue Growth

Year-on-year quarterly revenue growth declined by 5.9%, now sitting on 12.21B for the twelve trailing months.

More news about Momo.

2. Puyi (PUYI) – -21.17%

Puyi Inc. provides third-party wealth management services in China. The company distributes publicly raised fund and privately raised securities investment fund products through online and offline. It also provides asset management services that include managing fund of funds and non-performing loan funds; and corporate financing services. Puyi Inc. was incorporated in 2018 and is headquartered in Guangzhou, China.

NASDAQ ended the session with Puyi sliding 21.17% to $6.74 on Thursday, following the last session’s downward trend. NASDAQ fell 0.3% to $16,128.53, following the last session’s downward trend on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, Puyi has a trailing twelve months EPS of $-0.1.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -18.27%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 47.3%, now sitting on 114.44M for the twelve trailing months.

Volume

Today’s last reported volume for Puyi is 10571 which is 9% above its average volume of 9698.

Moving Average

Puyi’s value is higher than its 50-day moving average of $6.61 and way above its 200-day moving average of $5.59.

More news about Puyi.

3. Futu Holdings (FUTU) – -13.76%

Futu Holdings Limited provides digitalized securities brokerage and wealth management product distribution service in Hong Kong and internationally. It offers online financial services, including securities and derivative trades brokerage, margin financing and fund distribution services through its Futubull and Moomoo digital platforms. The company also provides financial information and online community services; online wealth management services under the brand of Money Plus through its Futubull and moomoo platforms, which give access to mutual funds, private funds, and bonds; market data and information services; and NiuNiu Community, which serves as an open forum for users and clients to share insights, ask questions, and exchange ideas. In addition, the company provides initial public offering subscription and employee share option plan solution services. Futu Holdings Limited was founded in 2007 and is based in Sheung Wan, Hong Kong.

NASDAQ ended the session with Futu Holdings falling 13.76% to $56.40 on Thursday while NASDAQ dropped 0.3% to $16,128.53.

Earnings Per Share

As for profitability, Futu Holdings has a trailing twelve months EPS of $3.97.

PE Ratio

Futu Holdings has a trailing twelve months price to earnings ratio of 14.21. Meaning, the purchaser of the share is investing $14.21 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.95%.

Yearly Top and Bottom Value

Futu Holdings’s stock is valued at $56.40 at 17:32 EST, way under its 52-week high of $67.49 and way higher than its 52-week low of $35.91.

More news about Futu Holdings.

4. PAVmed (PAVM) – -13.6%

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

NASDAQ ended the session with PAVmed dropping 13.6% to $2.16 on Thursday, following the last session’s downward trend. NASDAQ fell 0.3% to $16,128.53, following the last session’s downward trend on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, PAVmed has a trailing twelve months EPS of $-10.5.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1358.06%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 45.2% and 37.2%, respectively.

Volume

Today’s last reported volume for PAVmed is 33615 which is 55.82% below its average volume of 76100.

Yearly Top and Bottom Value

PAVmed’s stock is valued at $2.16 at 17:32 EST, way under its 52-week high of $9.36 and way higher than its 52-week low of $1.60.

Moving Average

PAVmed’s value is way below its 50-day moving average of $2.60 and way below its 200-day moving average of $4.26.

More news about PAVmed.

5. Phunware (PHUN) – -11.54%

Phunware, Inc., together with its subsidiaries, offers integrated software platform that equips companies with the products, solutions, and services to engage, manage, and monetize their mobile application portfolios in the United States and internationally. The company's products and services include cloud-based mobile software that licenses in software development kits (SDKs) form utilized inside mobile applications, such as analytics that provides data related to application use and engagement; content management that allows application administrators to create and manage app content in a cloud-based portal; alerts, notifications, and messaging; marketing automation that enables location-triggered messages and workflow; advertising; and location-based services that include mapping, navigation, wayfinding, workflow, asset management, and policy enforcement. It also engages the integration of its SDK licenses into existing applications maintained by its customers, as well as custom application development and support services; provision of cloud-based vertical solutions for healthcare, retail, sports, aviation, real estate, hospitality, education, and other applications; offering application transactions, including re-occurring and one-time transactional media purchases for application discovery, user acquisition and audience building, audience engagement, and audience monetization; and pre-packaged and custom high-end personal computer systems for gaming, streaming, and cryptocurrency mining enthusiasts. The company was founded in 2009 and is headquartered in Austin, Texas.

NASDAQ ended the session with Phunware sliding 11.54% to $9.20 on Thursday while NASDAQ dropped 0.3% to $16,128.53.

Earnings Per Share

As for profitability, Phunware has a trailing twelve months EPS of $-18.5.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -624.91%.

More news about Phunware.

6. Redfin (RDFN) – -11.24%

Redfin Corporation operates as a residential real estate brokerage company in the United States and Canada. The company operates an online real estate marketplace and provides real estate services, including assisting individuals in the purchase or sell of home. It also provides title and settlement services; and originates and sells mortgages. In addition, the company uses digital platforms to connect consumers with rental properties. The company was formerly known as Appliance Computing Inc. and changed its name to Redfin Corporation in May 2006. Redfin Corporation was incorporated in 2002 and is headquartered in Seattle, Washington.

NASDAQ ended the session with Redfin dropping 11.24% to $6.32 on Thursday while NASDAQ dropped 0.3% to $16,128.53.

Earnings Per Share

As for profitability, Redfin has a trailing twelve months EPS of $-1.13.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -172.46%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is a negative 3.6% and a negative 4%, respectively.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Redfin’s EBITDA is 1.74.

Revenue Growth

Year-on-year quarterly revenue growth declined by 1.7%, now sitting on 976.67M for the twelve trailing months.

More news about Redfin.

7. Relay Therapeutics (RLAY) – -10.61%

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

NASDAQ ended the session with Relay Therapeutics sliding 10.61% to $8.17 on Thursday while NASDAQ dropped 0.3% to $16,128.53.

Earnings Per Share

As for profitability, Relay Therapeutics has a trailing twelve months EPS of $-2.79.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -40.18%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Relay Therapeutics’s EBITDA is 19.74.

Yearly Top and Bottom Value

Relay Therapeutics’s stock is valued at $8.17 at 17:32 EST, way below its 52-week high of $19.23 and way higher than its 52-week low of $5.95.

More news about Relay Therapeutics.

8. MicroVision (MVIS) – -10.17%

MicroVision, Inc. develops and sells lidar sensors and software used in automotive safety and autonomous driving applications. It offers a suite of light detection and ranging (lidar) sensors and perception; and validation software for automotive OEMs, advanced driver-assistance systems, and autonomous vehicle applications, as well as non-automotive applications including industrial, robotics, and smart infrastructure. The company also provides MAVIN DR, a dynamic view lidar system, which combines short, medium, and long range sense and field of view into one form; lidar sensors under the MOVIA brand name; and MOSAIK, a software that automates manual data classification or annotation process. In addition, it provides engineering services for its hardware and software products. The company markets its products to customers directly, through trade shows, and its website. MicroVision, Inc. was founded in 1993 and is headquartered in Redmond, Washington.

NASDAQ ended the session with MicroVision sliding 10.17% to $2.08 on Thursday while NASDAQ fell 0.3% to $16,128.53.

Earnings Per Share

As for profitability, MicroVision has a trailing twelve months EPS of $-0.45.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -89.3%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

MicroVision’s EBITDA is -15.3.

More news about MicroVision.

9. Viking Therapeutics (VKTX) – -9.6%

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

NASDAQ ended the session with Viking Therapeutics falling 9.6% to $65.05 on Thursday while NASDAQ slid 0.3% to $16,128.53.

Earnings Per Share

As for profitability, Viking Therapeutics has a trailing twelve months EPS of $-0.91.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -34.79%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is a negative 12% and a negative 47.4%, respectively.

Moving Average

Viking Therapeutics’s value is way higher than its 50-day moving average of $35.73 and way higher than its 200-day moving average of $20.13.

Volatility

Viking Therapeutics’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.39%, a negative 1.57%, and a positive 4.92%.

Viking Therapeutics’s highest amplitude of average volatility was 6.28% (last week), 8.07% (last month), and 4.92% (last quarter).

More news about Viking Therapeutics.

10. Oportun Financial Corporation (OPRT) – -9.2%

Oportun Financial Corporation provides financial services. It offers personal loans and credit cards. The company serves customers through online and over-the-phone, as well as through retail and Lending as a Service partner locations. Oportun Financial Corporation was founded in 2005 and is headquartered in San Carlos, California.

NASDAQ ended the session with Oportun Financial Corporation dropping 9.2% to $3.65 on Thursday while NASDAQ dropped 0.3% to $16,128.53.

Earnings Per Share

As for profitability, Oportun Financial Corporation has a trailing twelve months EPS of $-4.05.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -37.81%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 103.1% and 250%, respectively.

Sales Growth

Oportun Financial Corporation’s sales growth is 5.1% for the present quarter and negative 2.9% for the next.

Previous days news about Oportun Financial Corporation

  • Oportun financial corporation (oprt) reports Q4 loss, tops revenue estimates. According to Zacks on Tuesday, 12 March, "While Oportun Financial Corporation has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"

More news about Oportun Financial Corporation.

Stay up to date with our winners and losers daily report

Leave a Reply

Your email address will not be published. Required fields are marked *